Staff

Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden

Findings presented at the International VT Symposium and published simultaneously in Circulation. CARDIFF-BY-THE-SEA, Calif. and PHILADELPHIA, Oct. 10, 2025 /PRNewswire/...

error: Content is protected !!